{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T02:38:17Z","timestamp":1776998297250,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["T32 HD091058"],"award-info":[{"award-number":["T32 HD091058"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005217","name":"National Center for Injury Prevention and Control","doi-asserted-by":"publisher","award":["R49CE003568"],"award-info":[{"award-number":["R49CE003568"]}],"id":[{"id":"10.13039\/100005217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["R01CE003471"],"award-info":[{"award-number":["R01CE003471"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Our study examines how harm reduction service providers (providers) throughout North Carolina (NC) provide services to people who use opioids (PWUO), how these service provision strategies align with PWUO preferences, and implications for care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted semi-structured in-depth interviews and used a thematic analytic strategy to identify common approaches to service delivery among providers (n\u2009=\u200910), rationales for taking these approaches, and how approaches were received by PWUO (n\u2009=\u200930). To be included in the study, service providers had to provide direct care to PWUO, while PWUO had to be 18\u2009+\u2009and be in active opioid use (not as prescribed by a doctor); providers and PWUO had to live in NC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Providers often allowed PWUO to take the lead in service delivery interactions, asked limited questions about what\/how participants use drugs, and rarely offered unsolicited information. Providers believed questioning could feel invasive or stigmatizing to PWUO. They also thought questions were unnecessary, assuming PWUO understood the risks that come with drug use. Providers reported that they would take the lead in interactions to correct PWUO\u2019s misconceptions that could make their use more dangerous, and would, occasionally, offer unsolicited information related to upcoming events or new services, or if PWUO appeared open to receiving more information. PWUO varied in desired approach by providers, based on the established rapport between providers and PWUO, and whether PWUO were in withdrawal during the interaction. Still, PWUO generally felt syringe service programs were a safe space, and many wanted to be asked more about their use so providers could provide tailored information about risks, trends, and safe use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Providers offer valuable services and safe spaces for PWUO in NC, but should ask program participants\u2019 preferences regarding interaction style to ensure the services provided are aligned with the desires of PWUO to have the maximum possible impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-026-01440-y","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:16:38Z","timestamp":1773746198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cNo judgment, no preaching\u201d: approaches to harm reduction service provision for people who use drugs in North Carolina"],"prefix":"10.1186","volume":"23","author":[{"given":"David C.","family":"Colston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adams L.","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Joniak-Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary L.","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica E.","family":"Swilley-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian W.","family":"Pence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian F.","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabbar I.","family":"Ranapurwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"1440_CR1","unstructured":"Ahmad F, Cisewski J, Rossen L, Sutton P. Provisional drug overdose death counts. 2024. Accessed 3 Aug 2024. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"1440_CR2","unstructured":"NC Department of health and human services division of public health. North Carolina Overdose Epidemic Data. 2025. Accessed 28 Oct 2025. https:\/\/www.dph.ncdhhs.gov\/programs\/chronic-disease-and-injury\/injury-and-violence-prevention-branch\/north-carolina-overdose-epidemic-data"},{"key":"1440_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. Int J Drug Policy. 2017;46:107\u201311. https:\/\/doi.org\/10.1016\/j.drugpo.2017.06.010.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1440_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/yco.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psych. 2021;34(4):344\u201350. https:\/\/doi.org\/10.1097\/yco.0000000000000717.","journal-title":"Curr Opin Psych"},{"issue":"Pt 2","key":"1440_CR5","doi-asserted-by":"publisher","first-page":"106541","DOI":"10.1016\/j.ypmed.2021.106541","volume":"152","author":"RA Jenkins","year":"2021","unstructured":"Jenkins RA. The fourth wave of the US opioid epidemic and its implications for the rural US: a federal perspective. Prev Med. 2021;152(Pt 2):106541. https:\/\/doi.org\/10.1016\/j.ypmed.2021.106541.","journal-title":"Prev Med"},{"key":"1440_CR6","doi-asserted-by":"publisher","first-page":"107625","DOI":"10.1016\/j.ypmed.2023.107625","volume":"176","author":"RA Rawson","year":"2023","unstructured":"Rawson RA, Erath TG, Clark HW. The fourth wave of the overdose crisis: examining the prominent role of psychomotor stimulants with and without fentanyl. Prev Med. 2023;176:107625. https:\/\/doi.org\/10.1016\/j.ypmed.2023.107625.","journal-title":"Prev Med"},{"key":"1440_CR7","doi-asserted-by":"publisher","first-page":"918197","DOI":"10.3389\/fpsyt.2022.918197","volume":"13","author":"S Ahmed","year":"2022","unstructured":"Ahmed S, Sarfraz Z, Sarfraz A. Editorial: a changing epidemic and the rise of opioid-stimulant co-use. Front Psychiatry. 2022;13:918197. https:\/\/doi.org\/10.3389\/fpsyt.2022.918197.","journal-title":"Front Psychiatry"},{"key":"1440_CR8","doi-asserted-by":"publisher","first-page":"104154","DOI":"10.1016\/j.drugpo.2023.104154","volume":"120","author":"T Quijano","year":"2023","unstructured":"Quijano T, Crowell J, Eggert K, et al. Xylazine in the drug supply: emerging threats and lessons learned in areas with high levels of adulteration. Int J Drug Policy. 2023;120:104154. https:\/\/doi.org\/10.1016\/j.drugpo.2023.104154.","journal-title":"Int J Drug Policy"},{"key":"1440_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.15585\/mmwr.mm7235a3","volume":"72","author":"J O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell J, Tanz L, Miller K, et al. Drug overdose deaths with evidence of counterfeit pill use \u2014 United States, July 2019\u2013December 2021. MMWR Morb Mortal Wkly Rep. 2023;72:949\u201356. https:\/\/doi.org\/10.15585\/mmwr.mm7235a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"1440_CR10","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.7326\/M23-2001","volume":"176","author":"J D\u2019Orazio","year":"2023","unstructured":"D\u2019Orazio J, Nelson L, Perrone J, Wightman R, Haroz R. Xylazine adulteration of the heroin\u2013fentanyl drug supply. Ann Intern Med. 2023;176(10):1370\u20136.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1440_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/15563650.2024.2309326","volume":"62","author":"HL Hays","year":"2024","unstructured":"Hays HL, Spiller HA, DeRienz RT, et al. Evaluation of the relationship of xylazine and fentanyl blood concentrations among fentanyl-associated fatalities. Clin Toxicol Phila. 2024;62(1):26\u201331. https:\/\/doi.org\/10.1080\/15563650.2024.2309326.","journal-title":"Clin Toxicol Phila"},{"issue":"4","key":"1440_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/injuryprev-2020-043968","volume":"27","author":"J Johnson","year":"2021","unstructured":"Johnson J, Pizzicato L, Johnson C, Viner K. Increasing presence of xylazine in heroin and\/or fentanyl deaths, Philadelphia, Pennsylvania, 2010\u20132019. Injury Prev. 2021;27(4):395\u20138. https:\/\/doi.org\/10.1136\/injuryprev-2020-043968.","journal-title":"Injury Prev"},{"key":"1440_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cca.2021.07.010","volume":"521","author":"WR Korn","year":"2021","unstructured":"Korn WR, Stone MD, Haviland KL, Toohey JM, Stickle DF. High prevalence of xylazine among fentanyl screen-positive urines from hospitalized patients, Philadelphia, 2021. Clin Chim Acta. 2021;521:151\u20134. https:\/\/doi.org\/10.1016\/j.cca.2021.07.010.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"1440_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","volume":"70","author":"C Mattson","year":"2021","unstructured":"Mattson C, Tanz L, Quinn K, Kariisa M, Patel P, Davis N. Trends and geographic patterns in drug and synthetic opioid overdose deaths \u2013 United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm7006a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1440_CR15","unstructured":"National Center for Health Statistics. U.S. Overdose Deaths Decrease in 2023, First Time Since 2018. 2024. Accessed 15 Nov 2024. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2024\/20240515.htm"},{"key":"1440_CR16","doi-asserted-by":"publisher","first-page":"109048","DOI":"10.1016\/j.drugalcdep.2021.109048","volume":"228","author":"KY Shiue","year":"2021","unstructured":"Shiue KY, Austin AE, Proescholdbell S, Cox ME, Aurelius M, Naumann RB. Literal text analysis of poly-class and polydrug overdose deaths in North Carolina, 2015\u20132019. Drug Alcohol Depend. 2021;228:109048. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109048.","journal-title":"Drug Alcohol Depend"},{"key":"1440_CR17","doi-asserted-by":"publisher","first-page":"108504","DOI":"10.1016\/j.drugalcdep.2020.108504","volume":"219","author":"MC Figgatt","year":"2021","unstructured":"Figgatt MC, Austin AE, Cox ME, Proescholdbell S, Marshall SW, Naumann RB. Trends in unintentional polysubstance overdose deaths and individual and community correlates of polysubstance overdose, North Carolina, 2009-2018. Drug Alcohol Depend. 2021;219:108504. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108504.","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"1440_CR18","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2105\/ajph.90.12.1933","volume":"90","author":"MA Marx","year":"2000","unstructured":"Marx MA, Crape B, Brookmeyer RS, et al. Trends in crime and the introduction of a needle exchange program. Am J Public Health. 2000;90(12):1933\u20136. https:\/\/doi.org\/10.2105\/ajph.90.12.1933.","journal-title":"Am J Public Health"},{"issue":"1","key":"1440_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12889-017-4210-2","volume":"17","author":"RM Fernandes","year":"2017","unstructured":"Fernandes RM, Cary M, Duarte G, et al. Effectiveness of needle and syringe programmes in people who inject drugs - an overview of systematic reviews. BMC Public Health. 2017;17(1):309. https:\/\/doi.org\/10.1186\/s12889-017-4210-2.","journal-title":"BMC Public Health"},{"issue":"33","key":"1440_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.15585\/mmwr.mm6933a2","volume":"69","author":"BH Lambdin","year":"2020","unstructured":"Lambdin BH, Bluthenthal RN, Wenger LD, et al. Overdose education and naloxone distribution within syringe service programs - United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(33):1117\u201321. https:\/\/doi.org\/10.15585\/mmwr.mm6933a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1440_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100757","author":"BR Ray","year":"2024","unstructured":"Ray BR, Humphrey JL, Patel SV, et al. Comparing harm reduction and overdose response services between community-based and public health department syringe service programmes using a national cross-sectional survey. Lancet Reg Health Am. 2024. https:\/\/doi.org\/10.1016\/j.lana.2024.100757.","journal-title":"Lancet Reg Health Am"},{"issue":"1","key":"1440_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12954-023-00755-4","volume":"20","author":"BH Lambdin","year":"2023","unstructured":"Lambdin BH, Wenger L, Bluthenthal R, et al. How do contextual factors influence naloxone distribution from syringe service programs in the USA: a cross-sectional study. Harm Reduct J. 2023;20(1):26. https:\/\/doi.org\/10.1186\/s12954-023-00755-4.","journal-title":"Harm Reduct J"},{"issue":"2","key":"1440_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/aje\/kwab233","volume":"191","author":"N Dasgupta","year":"2021","unstructured":"Dasgupta N, Figgatt MC. Invited commentary: drug checking for novel insights into the unregulated drug supply. Am J Epidemiol. 2021;191(2):248\u201352. https:\/\/doi.org\/10.1093\/aje\/kwab233.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"1440_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12954-023-00879-7","volume":"20","author":"CM Zagorski","year":"2023","unstructured":"Zagorski CM, Hosey RA, Moraff C, et al. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J. 2023;20(1):141. https:\/\/doi.org\/10.1186\/s12954-023-00879-7.","journal-title":"Harm Reduct J"},{"issue":"Suppl 1","key":"1440_CR25","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.drugalcdep.2009.05.019","volume":"105","author":"N Dasgupta","year":"2009","unstructured":"Dasgupta N, Schnoll SH. Signal detection in post-marketing surveillance for controlled substances. Drug Alcohol Depend. 2009;105(Suppl 1):S33-41. https:\/\/doi.org\/10.1016\/j.drugalcdep.2009.05.019.","journal-title":"Drug Alcohol Depend"},{"key":"1440_CR26","doi-asserted-by":"publisher","first-page":"103643","DOI":"10.1016\/j.drugpo.2022.103643","volume":"103","author":"MK Reed","year":"2022","unstructured":"Reed MK, Guth A, Salcedo VJ, Hom JK, Rising KL. \u201cYou can\u2019t go wrong being safe\u201d: motivations, patterns, and context surrounding use of fentanyl test strips for heroin and other drugs. Int J Drug Policy. 2022;103:103643. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103643.","journal-title":"Int J Drug Policy"},{"key":"1440_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.drugpo.2018.09.009","volume":"61","author":"MS Krieger","year":"2018","unstructured":"Krieger MS, Goedel WC, Buxton JA, et al. Use of rapid fentanyl test strips among young adults who use drugs. Int J Drug Policy. 2018;61:52\u20138. https:\/\/doi.org\/10.1016\/j.drugpo.2018.09.009.","journal-title":"Int J Drug Policy"},{"key":"1440_CR28","doi-asserted-by":"publisher","first-page":"102900","DOI":"10.1016\/j.drugpo.2020.102900","volume":"84","author":"NP Weicker","year":"2020","unstructured":"Weicker NP, Owczarzak J, Urquhart G, et al. Agency in the fentanyl era: exploring the utility of fentanyl test strips in an opaque drug market. Int J Drug Policy. 2020;84:102900. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102900.","journal-title":"Int J Drug Policy"},{"issue":"8","key":"1440_CR29","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2105\/ajph.2022.306881","volume":"112","author":"RS Alexander","year":"2022","unstructured":"Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022;112(8):1212\u20136. https:\/\/doi.org\/10.2105\/ajph.2022.306881.","journal-title":"Am J Public Health"},{"issue":"3","key":"1440_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/her\/cyn004","volume":"23","author":"RP Hawkins","year":"2008","unstructured":"Hawkins RP, Kreuter M, Resnicow K, Fishbein M, Dijkstra A. Understanding tailoring in communicating about health. Health Educ Res. 2008;23(3):454\u201366. https:\/\/doi.org\/10.1093\/her\/cyn004.","journal-title":"Health Educ Res"},{"key":"1440_CR31","doi-asserted-by":"publisher","DOI":"10.4172\/2324-9005.1000106","author":"M Kulesza","year":"2013","unstructured":"Kulesza M, Larimer ME, Rao D. Substance use related stigma: what we know and the way forward. J Addict Behav Ther Rehabil. 2013. https:\/\/doi.org\/10.4172\/2324-9005.1000106.","journal-title":"J Addict Behav Ther Rehabil"},{"issue":"10","key":"1440_CR32","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1176\/appi.ps.201400140","volume":"65","author":"CL Barry","year":"2014","unstructured":"Barry CL, McGinty EE, Pescosolido BA, Goldman HH. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr Serv. 2014;65(10):1269\u201372. https:\/\/doi.org\/10.1176\/appi.ps.201400140.","journal-title":"Psychiatr Serv"},{"issue":"2","key":"1440_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1468017308101818","volume":"9","author":"PW Corrigan","year":"2009","unstructured":"Corrigan PW, Kuwabara SA, O\u2019Shaughnessy J. The public stigma of mental illness and drug addiction: findings from a stratified random sample. J Soc Work. 2009;9(2):139\u201347. https:\/\/doi.org\/10.1177\/1468017308101818.","journal-title":"J Soc Work"},{"issue":"1","key":"1440_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","volume":"17","author":"B Muncan","year":"2020","unstructured":"Muncan B, Walters SM, Ezell J, Ompad DC. \u201cThey look at us like junkies\u201d: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53. https:\/\/doi.org\/10.1186\/s12954-020-00399-8.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1440_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC van Boekel","year":"2013","unstructured":"van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1):23\u201335. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.02.018.","journal-title":"Drug Alcohol Depend"},{"key":"1440_CR36","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.drugalcdep.2014.08.018","volume":"144","author":"H Wilson","year":"2014","unstructured":"Wilson H, Brener L, Mao L, Treloar C. Perceived discrimination and injecting risk among people who inject drugs attending Needle and Syringe Programmes in Sydney Australia. Drug Alcohol Depend. 2014;144:274\u20138. https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.08.018.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"1440_CR37","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/0049124118799377","volume":"50","author":"NM Deterding","year":"2021","unstructured":"Deterding NM, Waters MC. Flexible coding of in-depth interviews: a twenty-first-century approach. Sociol Methods Res. 2021;50(2):708\u201339. https:\/\/doi.org\/10.1177\/0049124118799377.","journal-title":"Sociol Methods Res"},{"key":"1440_CR38","unstructured":"Saldana J. The coding manual for qualitative researchers. 4 ed. SAGE; 2021."},{"issue":"2","key":"1440_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"issue":"5","key":"1440_CR40","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/10826084.2023.2294968","volume":"59","author":"AB Collins","year":"2024","unstructured":"Collins AB, Kaplowitz E, Bastani P, et al. \u201cI Don\u2019t Go Overboard\u201d: perceptions of overdose risk and risk reduction strategies among people who use drugs in Rhode Island. Subst Use Misuse. 2024;59(5):673\u20139. https:\/\/doi.org\/10.1080\/10826084.2023.2294968.","journal-title":"Subst Use Misuse"},{"issue":"3","key":"1440_CR41","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/00914509231164764","volume":"50","author":"K Hanoa","year":"2023","unstructured":"Hanoa K, Buvik K, Karlsson B. Death holds no fear: overdose risk perceptions among people who inject drugs. Contemp Drug Probl. 2023;50(3):312\u201327. https:\/\/doi.org\/10.1177\/00914509231164764.","journal-title":"Contemp Drug Probl"},{"issue":"1","key":"1440_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13676260600983668","volume":"10","author":"GP Hunt","year":"2007","unstructured":"Hunt GP, Evans K, Kares F. Drug use and meanings of risk and pleasure. J Youth Stud. 2007;10(1):73\u201396. https:\/\/doi.org\/10.1080\/13676260600983668.","journal-title":"J Youth Stud"},{"issue":"1","key":"1440_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12954-023-00893-9","volume":"20","author":"D Frank","year":"2023","unstructured":"Frank D, Elliott L, Cleland CM, et al. \u201cAs safe as possible\u201d: a qualitative study of opioid withdrawal and risk behavior among people who use illegal opioids. Harm Reduct J. 2023;20(1):158. https:\/\/doi.org\/10.1186\/s12954-023-00893-9.","journal-title":"Harm Reduct J"},{"key":"1440_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.drugpo.2019.04.006","volume":"70","author":"CM Jones","year":"2019","unstructured":"Jones CM. Syringe services programs: an examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S. Int J Drug Policy. 2019;70:22\u201332. https:\/\/doi.org\/10.1016\/j.drugpo.2019.04.006.","journal-title":"Int J Drug Policy"},{"key":"1440_CR45","doi-asserted-by":"publisher","first-page":"100593","DOI":"10.1016\/j.ssmqr.2025.100593","volume":"8","author":"CF Akiba","year":"2025","unstructured":"Akiba CF, Megerian CE, Chung EO, et al. The role of stigma in impeding implementation of harm reduction services in San Francisco. SSM Qual Res Health. 2025;8:100593. https:\/\/doi.org\/10.1016\/j.ssmqr.2025.100593.","journal-title":"SSM Qual Res Health"},{"issue":"4","key":"1440_CR46","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2105\/ajph.2024.307583","volume":"114","author":"SN Facente","year":"2024","unstructured":"Facente SN, Humphrey JL, Akiba C, et al. Funding and delivery of syringe services programs in the United States, 2022. Am J Public Health. 2024;114(4):435\u201343. https:\/\/doi.org\/10.2105\/ajph.2024.307583.","journal-title":"Am J Public Health"},{"key":"1440_CR47","unstructured":"Opioid Data Lab. Updated October 28, 2025. Accessed 28 Oct 28, 2025. https:\/\/www.opioiddata.org"},{"key":"1440_CR48","doi-asserted-by":"publisher","first-page":"112390","DOI":"10.1016\/j.drugalcdep.2024.112390","volume":"263","author":"R Jawa","year":"2024","unstructured":"Jawa R, Ismail S, Shang M, et al. Drug use practices and wound care experiences in the age of xylazine adulteration. Drug Alcohol Depend. 2024;263:112390. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.112390.","journal-title":"Drug Alcohol Depend"},{"issue":"15","key":"1440_CR49","doi-asserted-by":"publisher","first-page":"266","DOI":"10.15585\/mmwr.mm7415a2","volume":"74","author":"S Huo","year":"2025","unstructured":"Huo S, London K, Murphy L, et al. Notes from the field: suspected medetomidine withdrawal syndrome among Fentanyl-exposed patients - Philadelphia, Pennsylvania, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025;74(15):266\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm7415a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"1440_CR50","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1111\/dar.70024","volume":"44","author":"AL Sibley","year":"2025","unstructured":"Sibley AL, Bedard ML, Tobias S, et al. Emergence of medetomidine in the unregulated drug supply and its association with hallucinogenic effects. Drug Alcohol Rev. 2025;44(7):1896\u2013906. https:\/\/doi.org\/10.1111\/dar.70024.","journal-title":"Drug Alcohol Rev"},{"key":"1440_CR51","doi-asserted-by":"publisher","first-page":"209284","DOI":"10.1016\/j.josat.2023.209284","volume":"159","author":"AL Sibley","year":"2024","unstructured":"Sibley AL, Colston DC, Go VF. Interventions to reduce self-stigma in people who use drugs: a systematic review. J Subst Use Addict Treat. 2024;159:209284. https:\/\/doi.org\/10.1016\/j.josat.2023.209284.","journal-title":"J Subst Use Addict Treat"},{"issue":"12","key":"1440_CR52","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1080\/10826084.2016.1188951","volume":"51","author":"E Cama","year":"2016","unstructured":"Cama E, Brener L, Wilson H, von Hippel C. Internalized stigma among people who inject drugs. Subst Use Misuse. 2016;51(12):1664\u20138. https:\/\/doi.org\/10.1080\/10826084.2016.1188951.","journal-title":"Subst Use Misuse"},{"key":"1440_CR53","doi-asserted-by":"publisher","first-page":"103999","DOI":"10.1016\/j.drugpo.2023.103999","volume":"114","author":"AL Sibley","year":"2023","unstructured":"Sibley AL, Baker R, Levander XA, et al. \u201cI am not a junkie\u201d: Social categorization and differentiation among people who use drugs. Int J Drug Policy. 2023;114:103999. https:\/\/doi.org\/10.1016\/j.drugpo.2023.103999.","journal-title":"Int J Drug Policy"},{"key":"1440_CR54","doi-asserted-by":"publisher","first-page":"104237","DOI":"10.1016\/j.drugpo.2023.104237","volume":"122","author":"A Rains","year":"2023","unstructured":"Rains A, Sibley AL, Levander XA, et al. \u201cI would do anything but that\u201d: Attitudes towards sex work among rural people who use drugs. Int J Drug Policy. 2023;122:104237. https:\/\/doi.org\/10.1016\/j.drugpo.2023.104237.","journal-title":"Int J Drug Policy"},{"key":"1440_CR55","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.addbeh.2017.08.036","volume":"76","author":"C von Hippel","year":"2018","unstructured":"von Hippel C, Brener L, Horwitz R. Implicit and explicit internalized stigma: relationship with risky behaviors, psychosocial functioning and healthcare access among people who inject drugs. Addict Behav. 2018;76:305\u201311. https:\/\/doi.org\/10.1016\/j.addbeh.2017.08.036.","journal-title":"Addict Behav"},{"key":"1440_CR56","doi-asserted-by":"publisher","DOI":"10.1056\/CAT.17.0559","author":"NEJM Catalyst","year":"2017","unstructured":"Catalyst NEJM. What is patient-centered care? NEJM Catalyst. 2017. https:\/\/doi.org\/10.1056\/CAT.17.0559.","journal-title":"NEJM Catalyst"},{"issue":"6","key":"1440_CR57","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s11469-018-9930-8","volume":"17","author":"VA Earnshaw","year":"2019","unstructured":"Earnshaw VA, Bogart LM, Menino DD, et al. Disclosure, stigma, and social support among young people receiving treatment for substance use disorders and their caregivers: a qualitative analysis. Int J Ment Health Addict. 2019;17(6):1535\u201349. https:\/\/doi.org\/10.1007\/s11469-018-9930-8.","journal-title":"Int J Ment Health Addict"},{"issue":"5","key":"1440_CR58","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1177\/1049732319889354","volume":"30","author":"N Bergen","year":"2020","unstructured":"Bergen N, Labont\u00e9 R. Everything is perfect, and we have no problems\u201d: detecting and limiting social desirability bias in qualitative research. Qual Health Res. 2020;30(5):783\u201392. https:\/\/doi.org\/10.1177\/1049732319889354.","journal-title":"Qual Health Res"},{"key":"1440_CR59","unstructured":"NC Department of Health and Human Services Division of Public Health. North Carolina Safer Syringe Initiative. NC Department of Health and Human Services. Accessed 30 Oct 2025, 2025. https:\/\/www.dph.ncdhhs.gov\/programs\/chronic-disease-and-injury\/injury-and-violence-prevention-branch\/north-carolina-safer-syringe-initiative"},{"issue":"8","key":"1440_CR60","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2105\/ajph.2009.178467","volume":"100","author":"T Kerr","year":"2010","unstructured":"Kerr T, Small W, Buchner C, et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010;100(8):1449\u201353. https:\/\/doi.org\/10.2105\/ajph.2009.178467.","journal-title":"Am J Public Health"},{"issue":"2","key":"1440_CR61","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/jrh.12715","volume":"39","author":"EJ Batty","year":"2023","unstructured":"Batty EJ, Ibragimov U, Fadanelli M, et al. A qualitative analysis of rural syringe service program fidelity in Appalachian Kentucky: staff and participant perspectives. J Rural Health. 2023;39(2):328\u201337. https:\/\/doi.org\/10.1111\/jrh.12715.","journal-title":"J Rural Health"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01440-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01440-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01440-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:46:50Z","timestamp":1776995210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01440-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1440"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01440-y","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Materials and methods were approved by the University of North Carolina IRB (#23\u20130808). Written consent was received from participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. Extensive efforts were made to ensure anonymity and that participation in the study, or specific quotes, could not be traced to specific individuals when published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors have no competing or conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}